BICO Group AB (publ) (BICO.ST)
SEK 34.84
(5.07%)
SEK 34.84
(5.07%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 3.26 Billion SEK | 10.59% |
| 2021 | 2.95 Billion SEK | 2229.03% |
| 2020 | 126.74 Million SEK | 136.99% |
| 2019 | 53.48 Million SEK | 506.14% |
| 2018 | 8.82 Million SEK | -3.76% |
| 2017 | 9.16 Million SEK | 60.31% |
| 2016 | 5.71 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 2.93 Billion SEK | -4.62% |
| 2023 Q1 | 3.19 Billion SEK | -2.27% |
| 2023 Q2 | 3.07 Billion SEK | -3.65% |
| 2022 Q1 | 2.96 Billion SEK | 0.3% |
| 2022 Q4 | 3.26 Billion SEK | -4.75% |
| 2022 Q3 | 3.42 Billion SEK | 2.29% |
| 2022 Q2 | 3.35 Billion SEK | 13.17% |
| 2022 FY | 3.26 Billion SEK | 10.59% |
| 2021 Q4 | 2.95 Billion SEK | 25.09% |
| 2021 Q1 | 1.98 Billion SEK | 0.0% |
| 2021 FY | 2.95 Billion SEK | 2229.03% |
| 2021 Q2 | 2.26 Billion SEK | 13.72% |
| 2021 Q3 | 2.35 Billion SEK | 4.37% |
| 2020 FY | 126.74 Million SEK | 136.99% |
| 2020 Q3 | 126.74 Million SEK | 32.59% |
| 2020 Q1 | 89.29 Million SEK | 17.74% |
| 2020 Q2 | 95.58 Million SEK | 7.05% |
| 2019 Q2 | 23.75 Million SEK | -12.59% |
| 2019 Q1 | 27.18 Million SEK | 19.12% |
| 2019 Q3 | 53.48 Million SEK | 125.1% |
| 2019 FY | 53.48 Million SEK | 506.14% |
| 2019 Q4 | 75.83 Million SEK | 41.81% |
| 2018 Q2 | 10.69 Million SEK | 37.02% |
| 2018 FY | 8.82 Million SEK | -3.76% |
| 2018 Q4 | 22.81 Million SEK | 158.62% |
| 2018 Q3 | 8.82 Million SEK | -17.49% |
| 2018 Q1 | 7.8 Million SEK | 25.71% |
| 2017 Q2 | 7.8 Million SEK | -14.07% |
| 2017 Q4 | 6.2 Million SEK | -32.29% |
| 2017 FY | 9.16 Million SEK | 60.31% |
| 2017 Q1 | 9.08 Million SEK | -6.25% |
| 2017 Q3 | 9.16 Million SEK | 17.4% |
| 2016 FY | 5.71 Million SEK | 0.0% |
| 2016 Q4 | 9.69 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -29583.579% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | -22.078% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | -22.078% |
| Arcoma AB | 33.3 Million SEK | -9702.132% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | -890.173% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | -1066.345% |
| CellaVision AB (publ) | 212.32 Million SEK | -1437.563% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -22894.999% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -47426.991% |
| C-Rad AB (publ) | 122.4 Million SEK | -2567.157% |
| Duearity AB (publ) | 17.53 Million SEK | -18522.932% |
| Dignitana AB (publ) | 37.56 Million SEK | -8590.074% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -16387.879% |
| Getinge AB (publ) | 24.69 Billion SEK | 86.781% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -15747.338% |
| Iconovo AB (publ) | 14.55 Million SEK | -22331.112% |
| Integrum AB (publ) | 22.07 Million SEK | -14690.107% |
| Luxbright AB (publ) | 7 Million SEK | -46536.343% |
| Mentice AB (publ) | 163.55 Million SEK | -1896.038% |
| OssDsign AB (publ) | 105.25 Million SEK | -3001.551% |
| Paxman AB (publ) | 44.5 Million SEK | -7234.696% |
| Promimic AB (publ) | 16.15 Million SEK | -20106.736% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -5151.17% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -15242.607% |
| ScandiDos AB (publ) | 37.18 Million SEK | -8679.11% |
| Sectra AB (publ) | 1.64 Billion SEK | -98.898% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -7309.105% |
| Senzime AB (publ) | 58.06 Million SEK | -5522.32% |
| SpectraCure AB (publ) | 14.97 Million SEK | -21700.334% |
| Stille AB | 172.64 Million SEK | -1790.987% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 10.998% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | -1202.89% |